Rubius Therapeutics Inc., a Cambridge, Mass.-based company developing red blood cell-based therapies, has completed an oversubscribed $100 million crossover financing. Read More
The Saint Regis Mohawk Tribal Council is not waiting for the Patent Trial and Appeal Board (PTAB) to rule on the validity of six Restasis (cyclosporine) patents before appealing the board's decision that tribal sovereign immunity does not apply to inter partes review (IPR) proceedings. Read More
Jazz Pharmaceuticals plc, of Dublin, reported total revenue of $436.4 million for the fourth quarter, with full-year 2017 revenue coming in at $1.6 billion. Read More
Acceleron Pharma Inc., of Cambridge, Mass., highlighted the publication of final results from its phase I trial of ACE-083, a locally acting engineered protein therapeutic for the potential treatment of diseases such as facioscapulohumeral dystrophy (FSHD) and Charcot-Marie-Tooth disease. Read More
Beigene Ltd., of Beijing, said Revlimid (lenalidomide) was approved by the CFDA for the treatment of multiple myeloma (MM) in combination with dexamethasone in adult patients with previously untreated MM who are not eligible for transplant. Read More
Wize Pharma Inc., of Hod Hasharon, Israel, said it received notices from existing stockholders and lenders to exercise investment rights and warrants to purchase an aggregate of about 18.9 million shares of common stock. Read More
HONG KONG – The sheer speed of growth of the biotech and med-tech industries in China has easily outpaced the development of regulation and has led to concerns that too many of the ballooning number of clinical trials in the country fail to meet enrollment targets. Read More
As the November 2023 deadline for the full implementation of the Drug Supply Chain Security Act (DSCSA) approaches, the FDA continues to meet with stakeholders to work out some of the kinks. Read More
LONDON – The Novo Nordisk Foundation is making a move to plug the gap in the antibiotic pipeline, setting up a $165 million venture capital fund to invest in companies involved in discovery and early stage development. Read More
DUBLIN – The steady flow of capital into early stage biopharmaceutical innovation continues unabated, as evidenced by two separate transactions disclosed Wednesday. Astrazeneca plc's Medimmune arm is spinning out a series of pipeline assets into a new venture, Viela Bio Inc., which has secured funding commitments of up to $250 million from a syndicate of investors led by three funds with a strong Chinese orientation. Read More
